Verteporfin photodynamic therapy for neovascular age-related ...
Verteporfin photodynamic therapy for neovascular age-related ... Verteporfin photodynamic therapy for neovascular age-related ...
80 Acknowledgements■■■■■■Dr KA Muldrew contributed to the setting up of NetwORC UK. She designed the gradingprotocols with clinician colleagues, developed training and validation programmes andtrained staff employed in the reading centres. She worked on the quality assurance processesand contributed to the analyses.Dr T Peto is Head of the Moorfields Eye Hospital Reading Centre, part of NetwORC UK. Shewas involved in the setting up, design and execution of the imaging and grading protocol.She also contributed to the training and certification of graders, and advised clinicians aboutimage interpretation, together with the clinical leads from the Belfast and the Liverpoolreading centres.Professor U Chakravarthy designed the study with Professors Harding and Reeves and DrGrieve. She was the principal applicant in the effort to secure funding. She led the study and,with colleagues, the establishment and management of NetwORC UK, developed specificallyfor this project. She contributed to the interpretation of the results and drafted the reportwith Professors Harding and Reeves.All authors contributed to the reporting of the study through this report and other peer-reviewedpublications arising from the study.Verteporfin photodynamic therapy cohort study contributorsMr Douglas Newman, Addenbrookes Hospital, Cambridge.Mr Martin Harris, General Hospital, Barnet, London.Mr Richard Antcliffe, Royal United Hospital, Bath.Ms Salwa Abugreen, Royal Blackburn Hospital, Blackburn.Ms Clare Bailey, Bristol Eye Hospital, Bristol.Professor Usha Chakravarthy, Royal Victoria Hospital, Belfast.Mr Simon Morgan, Blackpool Victoria Hospital, Blackpool.Mr Jonathon Gibson, Birmingham and Midlands Eye Hospital, Birmingham.Mr Faruque Ganchi, Bradford Royal Infirmary, Bradford.Mr Anthony Casswell, Sussex Eye Hospital, Brighton.Mr Shafiq Rehman, Calderdale Royal Hospital, Calderdale, Yorkshire.Mr Robert Johnston, Cheltenham General Hospital, Cheltenham.Mr Sergio Pagliarini, University Hospitals Coventry and Warwickshire, Coventry.Mr Hean-Choon Chen, Derbyshire Royal Infirmary, Derby.Mrs Geeta Menon, Frimley Park Hospital, Frimley Park.Mr Sakkaf Aftab and Mr Satish Kotta, Northern Lincolnshire and Goole NHS Trust, Goole.Mr Gavin Walter, Harrogate District Hospital, Harrogate.Mr Kevin Gregory-Evans, Western Eye Hospital, London.Mr Nicholas Lee Hillingdon Hopsitals NHS Trust. Middlesex.Mr Meen Zaman, Hull Royal Infirmary, Hull.Mr Clive Edelsten, Ipswich Hospital NHS Trust, Ipswich.Mr Victor Chong, King’s College Hospital, London.Mr R J Pushpanathan, Queen Elizabeth Hospital, King’s Lynn.Mr Simon Horgan, Kingston Hospital, Kingston.Mr Martin McKibbin, Leeds Teaching Hospital, Leeds.Professor Simon Harding, Royal Liverpool University Hospital, Liverpool.Mr Frank Ahfat, Maidstone Hospital, Maidstone.Mr Paulo Stanga, Spire Manchester Hospital, Manchester.Mr Adnan Tufail, Moorfields Eye Hospital, Moorfields, London.Mr James Talks, Newcastle Upon Tyne Hospitals NHS Trust, Newcastle.Mr Andrew Glenn, Norfolk and Norwich University Hospital, Norwich.
DOI: 10.3310/hta16060Health Technology Assessment 2012; Vol. 16: No. 681Mr Alexander Foss, Queen’s Medical Centre, Nottingham.Ms Susan Downes, Oxford Eye Hospital, Oxford.Professor Bal Dhillon, Princess Alexandra Eye Pavillion, Edinburgh.Ms Sarah-Lucie Watson, Royal Berkshire Hospital, Reading.Mr Christopher Brand, Royal Hallamshire Hospital, Sheffield.Mr Niral Karia, Southend Hospital, Southend.Professor Andrew Lotery, Southampton University Hospital, Southampton.Mr Myer Mark Yodaiken, Stepping Hill Hospital, Stockport.Ms Consuela Moorman, Stoke Mandeville Hospital, Aylesbury.Mr Michael Cole, Torbay Hospital, Torbay.Mr Salim Natha, Leigh Infirmary, Wigan.Mr Yit C Yang, Wolverhampton Eye Infirmary, Wolverhampton.Mr Sal Rassam, Worthing Hospital, Worthing.Mr Gavin Walters, Harrogate District Hospital, Harrogate.Publications1. Harding SP, Tomlin K, Reeves BC, Langham J, Walker J, Carpenter J, et al. Verteporfinphotodynamic therapy cohort study: report 1: effectiveness and factors influencingoutcomes. Ophthalmology 2009;116:e1–8.2. Grieve R, Guerriero C, Walker J, Tomlin K, Langham J, Harding S, et al. Verteporfinphotodynamic therapy cohort study: report 3: cost effectiveness and lessons for futureevaluations. Ophthalmology 2009;116:2471–7.3. Reeves BC, Langham J, Walker J, Grieve R, Chakravarthy U, Tomlin K, et al. Verteporfinphotodynamic therapy cohort study: report 2: clinical measures of vision and health-relatedquality of life. Ophthalmology 2009;116:2463–70.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Reeves et al. under the terms of a commissioning contract issued by theSecretary of State for Health.
- Page 44 and 45: 30 Key changes to the protocolFor i
- Page 46 and 47: 32 Key changes to the protocolIn ad
- Page 48 and 49: 34 Key changes to the protocolsites
- Page 52 and 53: 38 Results (1) - study cohortTABLE
- Page 54 and 55: 40 Results (1) - study cohortTABLE
- Page 56 and 57: 42 Results (1) - study cohortTABLE
- Page 58 and 59: 44 Results (1) - study cohortTABLE
- Page 60 and 61: 46 Results (2) - objectives A, B, C
- Page 62 and 63: 48 Results (2) - objectives A, B, C
- Page 64 and 65: 50 Results (2) - objectives A, B, C
- Page 66 and 67: 52 Results (2) - objectives A, B, C
- Page 69 and 70: DOI: 10.3310/hta16060Health Technol
- Page 71 and 72: DOI: 10.3310/hta16060Health Technol
- Page 73 and 74: DOI: 10.3310/hta16060Health Technol
- Page 75 and 76: DOI: 10.3310/hta16060Health Technol
- Page 77: DOI: 10.3310/hta16060Health Technol
- Page 80 and 81: 66 Discussion of resultsStrengths a
- Page 82 and 83: 68 Discussion of resultsThe VPDT st
- Page 84 and 85: 70 Discussion of resultsOur analyse
- Page 86 and 87: 72 Discussion of resultsA further c
- Page 88 and 89: 74 Discussion of resultsVPDT. It is
- Page 91 and 92: DOI: 10.3310/hta16060Health Technol
- Page 93: DOI: 10.3310/hta16060Health Technol
- Page 98 and 99: 84 References16. Stelmack J. Qualit
- Page 100 and 101: 86 References49. Guymer RH, Chiu AW
- Page 102 and 103: 88 References83. Margrain TH. Minim
- Page 104 and 105: 90 Appendix 1THE VERTEPORFIN PHOTOD
- Page 106 and 107: 92 Appendix 11. Overview of Manual
- Page 108 and 109: 94 Appendix 1And, if also collectin
- Page 110 and 111: 96 Appendix 1more patients in the v
- Page 112 and 113: 98 Appendix 12.4 Limitations of the
- Page 114 and 115: 100 Appendix 1Box 2 Key advantages
- Page 116 and 117: 102 Appendix 14. Study population4.
- Page 118 and 119: 104 Appendix 15. Recruitment to the
- Page 120 and 121: 106 Appendix 16. Background data co
- Page 122 and 123: 108 Appendix 1Table 1: Schedule of
- Page 124 and 125: 110 Appendix 1The Verteporfin Photo
- Page 126 and 127: 112 Appendix 1• Additional clinic
- Page 128 and 129: 114 Appendix 18. Recording adverse
- Page 130 and 131: 116 Appendix 1level of benefit from
- Page 132 and 133: 118 Appendix 1• comparison of num
- Page 134 and 135: 120 Appendix 110.6 Sub-group analys
- Page 136 and 137: 122 Appendix 112. Data issues12.1 D
- Page 138 and 139: 124 Appendix 113. Organisation13.1
- Page 140 and 141: 126 Appendix 114. References[1] Ref
- Page 142 and 143: 128 Appendix 1Barnes RM, Gee L, Tay
DOI: 10.3310/hta16060Health Technology Assessment 2012; Vol. 16: No. 681Mr Alexander Foss, Queen’s Medical Centre, Nottingham.Ms Susan Downes, Ox<strong>for</strong>d Eye Hospital, Ox<strong>for</strong>d.Professor Bal Dhillon, Princess Alexandra Eye Pavillion, Edinburgh.Ms Sarah-Lucie Watson, Royal Berkshire Hospital, Reading.Mr Christopher Brand, Royal Hallamshire Hospital, Sheffield.Mr Niral Karia, Southend Hospital, Southend.Professor Andrew Lotery, Southampton University Hospital, Southampton.Mr Myer Mark Yodaiken, Stepping Hill Hospital, Stockport.Ms Consuela Moorman, Stoke Mandeville Hospital, Aylesbury.Mr Michael Cole, Torbay Hospital, Torbay.Mr Salim Natha, Leigh Infirmary, Wigan.Mr Yit C Yang, Wolverhampton Eye Infirmary, Wolverhampton.Mr Sal Rassam, Worthing Hospital, Worthing.Mr Gavin Walters, Harrogate District Hospital, Harrogate.Publications1. Harding SP, Tomlin K, Reeves BC, Langham J, Walker J, Carpenter J, et al. <strong>Verteporfin</strong><strong>photodynamic</strong> <strong>therapy</strong> cohort study: report 1: effectiveness and factors influencingoutcomes. Ophthalmology 2009;116:e1–8.2. Grieve R, Guerriero C, Walker J, Tomlin K, Langham J, Harding S, et al. <strong>Verteporfin</strong><strong>photodynamic</strong> <strong>therapy</strong> cohort study: report 3: cost effectiveness and lessons <strong>for</strong> futureevaluations. Ophthalmology 2009;116:2471–7.3. Reeves BC, Langham J, Walker J, Grieve R, Chakravarthy U, Tomlin K, et al. <strong>Verteporfin</strong><strong>photodynamic</strong> <strong>therapy</strong> cohort study: report 2: clinical measures of vision and health-<strong>related</strong>quality of life. Ophthalmology 2009;116:2463–70.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Reeves et al. under the terms of a commissioning contract issued by theSecretary of State <strong>for</strong> Health.
Change language